Market capitalization is the total value the stock market puts on a company: its share price multiplied by the number of shares outstanding. Each point here is the share count reported in a filing multiplied by the closing price on that filing date, adjusted for later stock splits, so the history moves when a new filing arrives rather than with each day's trading. A larger market cap means investors collectively value the company more highly; by itself it says nothing about profit or debt. Annual points keep the latest observation in each calendar year.
Lineage Cell Therapeutics, Inc. market cap for the quarter ending 2026-08-03 was $280.73M, a 23.40% increase year-over-year.
Lineage Cell Therapeutics, Inc. market cap for the quarter ending 2026-06-30 was $333.84M, a 60.14% increase year-over-year.
Lineage Cell Therapeutics, Inc. market cap for the quarter ending 2026-05-08 was $344.03M, a 242.40% increase year-over-year.
Lineage Cell Therapeutics, Inc. market cap for the quarter ending 2026-03-31 was $391.4M, a 280.88% increase year-over-year.
Lineage Cell Therapeutics, Inc. market cap for fiscal 2026 was $280.73M.
Lineage Cell Therapeutics, Inc. market cap for fiscal 2025 was $406.01M, a 268.41% increase from fiscal 2024.
Lineage Cell Therapeutics, Inc. market cap for fiscal 2024 was $110.21M, a 42.22% decline from fiscal 2023.
Lineage Cell Therapeutics, Inc. market cap for fiscal 2023 was $190.74M, a 4.16% decline from fiscal 2022.